Cara Therapeutics, Inc. (NASDAQ: CARA): An Overlooked Biotech Company In Multi-Billion CBD Market

Spotlight Growth - Penny Stocks, Small Cap Stocks, Micro-Cap and Micro Cap Stocks, Stock Exchange, NASDAQ, Crypto, BitCoin, DogeCoin, Ai, Artificial Intelligence, Chat GPT, OpenAi, Open Ai, ASURE Software, Trending, Now, Breaking News, BioTech, Data, Analytics, Technology, Big Tech, Banking, SVB, Bank Closures, Failures, Finance, Stock Market News, WeBull, RobinHood, Reddit Traders, Trading, Investing, Investors, Investment, Investments, Day Trading, Real Estate, VC, Venture Capital, Private Equity, Firm, Firms, OTC Markets, Public, Private, OTCQB, GOOG, APPLE, Shareholders, Stakeholders, Shares, Finance Education, Blog, Articles, Consumer Goods, Pharma, Commodities, Precious Metals, Gold, Silver, Cannabis, CBD, Lithium, Electric Vehicles, Solar, Tesla, Charging, EV, Cloud Computing, Wall Street Bets, Sports Betting, Economy, Economics, IPO, Trade Ideas, Intellectual Property Rights, Private Placement, Crowd Funding, Fundraising, Meta, Metaverse, Web 3, Cyber, Cybersecurity, Cyber Security, Aircraft, VPN, Yahoo Finance, Benzinga, BarChart.

In recent years, speculative investors have taken a liking to “marijuana” stocks. Most of these stocks are often high risk due to federal legislation still prohibiting marijuana use. This has led to an underdeveloped market surrounding the industry, especially its wall street counterpart. Investors in these stocks are usually hoping for either a change in federal legislation, or for more states to continue changing their regulatory laws. Today, I’d like to propose a way traders can benefit from changing regulations, but with a method less risky than usual marijuana stocks. This trade is buying stock in Cara Therapeutics, Inc. (NASDAQ: CARA).

Cara Therapeutics, Inc. is not a marijuana company by nature. It is actually a clinical stage biotechnology company. Their goal is to research non-addictive drugs capable of relieving pain and pruritis (chronic itching). Typically, pain medications are either non-steroidal anti-inflammatories, such as Ibuprofen, or opioids, such as morphine. Ibuprofen and other non-steroidals are relatively harmless, but there is currently an opioid crisis occurring across the nation. Currently availible prescription opioids act on the opioid receptors of the brain and have a strong potential to become addictive, and have other unwanted side effects.

Research on marijuana has led scientists to the discovery of a different kind of receptor, a cannabinoid receptor. There are CB1 receptors which are in the brain and associated with the high that comes from smoking or consuming marijuana. There are also CB2 receptors. These receptors play a role in pain and inflammation, but are found outside of the brain. Cara Therapeutics, Inc. has a drug in their pipeline called CR701, which is a cannabinoid. This drug targets the CB2 receptors, meaning it delivers reduction in pain and inflammation without causing a high. Cara Therapeutics, Inc. is considered a marijuana stock because CR701 is a cannabinoid, meaning it is tied to cannabis.

The main issue with investing in Cara Therapeutics, Inc. as a marijuana stock is that CR701 is only a fraction of their drug pipeline. It is currently only in phase I, and for those unfamiliar with FDA calendars, this means it could take years before it gets to the market. The drug in their pipeline that will really determine the stocks fate is CR845. This drug is not a cannabinoid, but it still aims to be a non-addictive opioid targeter. CR845 does not generate euphoria and pleasure in the same way that typical opioids do. Currently, Cara Therapeutics, Inc. has two versions of CR845 in its pipeline. One is dedicated to stopping post operational pain, and is in phase III which is the final phase before commercialization. The other is meant to treat chronic pain, and is in phase II of its clinical trial.

The fact that Cara’s cannabinoid technology is not their primary concern does not mean it is a bad investment. In fact, any chance at disrupting the opioid market should send Cara stock soaring. By 2021, it is estimated that the US opioid market capitalization will reach $17.7 billion. Doctors are currently making an effort to prescribe fewer opioids, and a non-addictive opioid pain drug would be monumental in this effort.

Even so, if more states or the federal government eases off on marijuana regulation, Cara Therapeutics, Inc. could see a spike. Retail investors would likely buy into the stock based on their belief that it is a “marijuana stock” so I do still recommend buying it if you’re looking for a way to trade marijuana legislation. Just be aware it will not be the main driver of profits, and price action will likely be more associated with CR845 events. If you are looking for a trade that will pay off in the next few years if legislation changes, I still recommend buying this stock. You will be investing in the success of cannabinoids, and the potential upside of the other drugs in Cara Therapeutics, Inc. pipeline remains enticing.

Disclosure: No positions are held in CARA and are not expected to be initiatied in the near future.

Cara Therapeutics, Inc. (NASDAQ: CARA): An Overlooked Biotech Company In Multi-Billion CBD Market

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

Vision Marine (NASDAQ: VMAR): An Innovative, Revenue-Producing Company Riding the Electric Boating Growth Trend

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

Telcoin (TEL) Continues to Demonstrate Fundamental Progress, Displaying Bullish Technical Setup

Grove Collaborative (NYSE: GROV) Expands Retail Distribution Footprint Into 2,200 Additional Stores

The Metaverse is Exploding in Popularity and Growth

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

Safe-T Group Ltd. (NASDAQ: SFET) to Participate at A.G.P.’s Virtual Emerging Growth Technology Conference on February 4, 2021

Nvidia Announces New Chip Specifically For Ethereum Mining

Sortis Holdings, Inc. (OTC Pink: SOHI) Announces Results for Second Quarter 2020

Medical Marijuana Coming Soon to Virginia

SushiSwap (SUSHI) Appropriates Uniswap’s Liquidity Pool by Preempting Native Token Release

Europe Shows Signs of Warming to SPACs

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)

Vivos Therapeutics (NASDAQ: VVOS) Secures Strategic Alliances to Enhance Clear Aligner Offerings and Bolster Revenue Streams

Shares of Soleno Therapeutics (NASDAQ: SLNO) Surge Over 500% After Its DCCR Candidate Shows Promise in PWS Clinical Trials

Understanding EBITDA and Adjusted EBITDA: A View Into Asure’s (NASDAQ: ASUR) Recent Financial Performance

From Microsoft to Travel Tech: VCI Global’s (NASDAQ: VCIG) Expanding AI Horizons

Singapore’s Leap into the Future of Cell and Gene Therapies

Asure (NASDAQ: ASUR) Completes Capital Raise to Fuel High-Interest Debt Reduction, Craig-Hallum Analyst Praises Move and Estimates Bullish Outcome

Asure (NASDAQ: ASUR) Reports Massive 50% Y/Y Revenue Growth During Q2 2023, Raises $40 Million to Pay Off High-Interest Debt and Fund Acquisitions

Recent News

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Categories

Site Navigation